Tectonic Therapeutic, Inc. Price & Performance (TECX)

Arvinas is cutting about one-third of its staff and halting two planned Phase 3 trials for its breast cancer drug vepdegestrant, citing financial considerations and evolving treatment competition. The company will focus on regulatory approval for a narrower patient group, aiming to extend its financial runway into late 2028.12

Several biotech firms, including Cyclacel Pharmaceuticals and Seres Therapeutics, have executed significant reverse splits, while others like Cutera and NeuroMetrix have been delisted following mergers or bankruptcies. These moves reflect ongoing volatility and consolidation within the small-cap biotech sector, impacting investor portfolios and market structure.34

Osisko Gold Royalties transitioned into OR Royalties, Inc. without a ticker change, while Tortoise North American Pipeline Fund underwent a corporate reorganization and CUSIP update. These actions, effective May 13, 2025, are part of broader efforts to streamline operations and enhance shareholder value in the resources and infrastructure sectors.35